Latest Period
Q4 2025
Security Snapshot
Krystal Biotech, Inc. - Common Stock (KRYS) Institutional Ownership
CUSIP: 501147102
13F Institutional Holders and Ownership History from Q3 2017 to Q1 2026
Institutions Reporting
331
Shares (Excl. Options)
28,422,214
Price
$246.54
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- KRYS on Nasdaq
- Shares outstanding
- 29,289,327
- Price per share
- $258.32
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 28,422,214
- Total reported value
- $7,006,786,218
- % of total 13F portfolios
- 0.01%
- Share change
- +281,754
- Value change
- +$81,339,251
- Number of holders
- 331
- Price from insider filings
- $258.32
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- KRYS - Krystal Biotech, Inc. - Common Stock is tracked under CUSIP 501147102.
- 331 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 331 to 72 between Q4 2025 and Q1 2026.
- Reported value moved from $7,006,786,218 to $101,017,983.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 331 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 501147102?
CUSIP 501147102 identifies KRYS - Krystal Biotech, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 501147102:
Significant Owners of Krystal Biotech, Inc. - Common Stock (KRYS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5% | $382,084,101 | 1,479,111 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| STATE STREET CORP | 4.4% | $218,154,766 | 1,278,975 | STATE STREET CORPORATION | 31 Dec 2024 |
As of 31 Dec 2025, 331 institutional investors reported holding 28,422,214 shares of Krystal Biotech, Inc. - Common Stock (KRYS). This represents 97% of the company’s total 29,289,327 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Krystal Biotech, Inc. - Common Stock (KRYS) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 4,349,628 | +0.19% | 0.05% | $1,072,357,209 |
| BlackRock, Inc. | 13% | 3,937,817 | +2.7% | 0.02% | $970,829,404 |
| Avoro Capital Advisors LLC | 9.9% | 2,888,888 | +4% | 7% | $712,226,448 |
| VANGUARD GROUP INC | 9.5% | 2,778,845 | -0.48% | 0.01% | $685,096,446 |
| STATE STREET CORP | 4.6% | 1,342,303 | -3.8% | 0.01% | $330,931,382 |
| Soleus Capital Management, L.P. | 3.2% | 941,059 | -7.6% | 9.8% | $232,008,686 |
| Capital World Investors | 2.8% | 809,500 | +0.03% | 0.03% | $199,574,130 |
| Redmile Group, LLC | 2.3% | 677,705 | +2.5% | 12% | $167,081,391 |
| Hood River Capital Management LLC | 2.1% | 613,302 | +1% | 1.7% | $151,203,475 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 611,878 | +0.1% | 0.01% | $150,878,011 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.8% | 529,955 | +13% | 0.01% | $130,656,000 |
| DIMENSIONAL FUND ADVISORS LP | 1.7% | 492,968 | -7.7% | 0.03% | $121,538,226 |
| Frazier Life Sciences Management, L.P. | 1.7% | 488,460 | -29% | 3.2% | $120,424,928 |
| Bellevue Group AG | 1.4% | 410,323 | +31175% | 1.9% | $101,161,033 |
| CITADEL ADVISORS LLC | 1.3% | 386,505 | -39% | 0.06% | $95,288,943 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.3% | 376,340 | +152% | 0.26% | $92,782,864 |
| GOLDMAN SACHS GROUP INC | 1% | 293,525 | -16% | 0.01% | $72,365,654 |
| NORGES BANK | 0.97% | 284,573 | 0.01% | $70,158,627 | |
| NORTHERN TRUST CORP | 0.84% | 247,443 | -0.29% | 0.01% | $61,004,597 |
| FIRST TRUST ADVISORS LP | 0.84% | 245,276 | -1.3% | 0.04% | $60,470,345 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.83% | 242,774 | -0.04% | 0.01% | $59,853,502 |
| MORGAN STANLEY | 0.76% | 221,481 | -5.6% | 0% | $54,604,696 |
| JANUS HENDERSON GROUP PLC | 0.75% | 219,440 | +2079% | 0.02% | $54,147,221 |
| BRAIDWELL LP | 0.69% | 202,101 | -61% | 1.6% | $49,825,981 |
| BANK OF AMERICA CORP /DE/ | 0.65% | 190,807 | +38% | 0% | $47,041,555 |
Institutional Holders of Krystal Biotech, Inc. - Common Stock (KRYS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 391,130 | $101,017,983 | -$21,134,184 | $258.32 | 72 |
| 2025 Q4 | 28,422,214 | $7,006,786,218 | +$81,339,251 | $246.54 | 331 |
| 2025 Q3 | 27,965,722 | $4,936,825,964 | +$84,621,791 | $176.53 | 281 |
| 2025 Q2 | 27,659,439 | $3,802,977,476 | -$846,440 | $137.46 | 274 |
| 2025 Q1 | 27,342,861 | $4,929,918,497 | -$51,223,771 | $180.30 | 298 |
| 2024 Q4 | 27,774,030 | $4,351,782,009 | -$92,533,890 | $156.66 | 264 |
| 2024 Q3 | 28,280,954 | $5,147,915,246 | -$55,463,849 | $182.03 | 281 |
| 2024 Q2 | 28,529,838 | $5,239,051,095 | +$658,436,118 | $183.64 | 245 |
| 2024 Q1 | 25,223,190 | $4,487,798,716 | +$175,442,652 | $177.93 | 233 |
| 2023 Q4 | 24,418,337 | $3,029,453,570 | +$42,716,131 | $124.06 | 194 |
| 2023 Q3 | 23,797,985 | $2,760,663,293 | +$92,606,023 | $116.00 | 187 |
| 2023 Q2 | 23,039,160 | $2,704,675,917 | +$256,730,169 | $117.40 | 182 |
| 2023 Q1 | 20,979,177 | $1,678,957,589 | +$9,326,151 | $80.06 | 159 |
| 2022 Q4 | 20,961,146 | $1,660,575,264 | -$15,716,124 | $79.22 | 153 |
| 2022 Q3 | 20,879,536 | $1,455,390,527 | +$2,509,281 | $69.70 | 141 |
| 2022 Q2 | 20,782,487 | $1,364,495,044 | +$17,501,639 | $65.66 | 129 |
| 2022 Q1 | 20,551,109 | $1,367,525,309 | +$24,889,158 | $66.54 | 129 |
| 2021 Q4 | 19,309,579 | $1,350,723,574 | +$209,084,528 | $69.95 | 135 |
| 2021 Q3 | 16,287,424 | $850,358,590 | -$12,114,445 | $52.21 | 112 |
| 2021 Q2 | 16,400,636 | $1,115,239,700 | -$7,228,383 | $68.00 | 113 |
| 2021 Q1 | 16,474,358 | $1,268,577,569 | +$201,515,888 | $77.04 | 113 |
| 2020 Q4 | 13,913,023 | $835,272,340 | -$16,214,267 | $60.00 | 107 |
| 2020 Q3 | 14,383,109 | $619,123,442 | +$11,279,105 | $43.05 | 98 |
| 2020 Q2 | 14,124,381 | $585,026,548 | +$106,373,347 | $41.42 | 108 |
| 2020 Q1 | 11,507,819 | $497,600,700 | -$9,385,943 | $43.24 | 88 |
| 2019 Q4 | 11,391,925 | $630,888,478 | +$15,766,941 | $55.38 | 89 |
| 2019 Q3 | 11,182,639 | $388,328,616 | +$48,273,351 | $34.73 | 83 |
| 2019 Q2 | 9,765,134 | $393,197,420 | +$130,560,730 | $40.27 | 75 |
| 2019 Q1 | 6,652,555 | $218,869,000 | +$15,470,940 | $32.90 | 56 |
| 2018 Q4 | 6,208,589 | $129,016,000 | +$73,086,744 | $20.78 | 45 |
| 2018 Q3 | 2,717,290 | $47,597,000 | +$6,006,830 | $17.58 | 21 |
| 2018 Q2 | 2,390,244 | $35,543,000 | -$7,828,421 | $14.87 | 16 |
| 2018 Q1 | 3,076,255 | $31,040,000 | -$1,629,988 | $10.09 | 12 |
| 2017 Q4 | 3,236,349 | $34,047,000 | +$1,027,245 | $10.52 | 13 |
| 2017 Q3 | 3,142,571 | $31,331,000 | +$31,331,000 | $9.97 | 13 |